RxDoctor Payments Data

Crystal Densmore

Physician Assistant · Elma, NYNPI 1659739936

Payments from drug & device makers

$9,552in general payments, 2019–2025

Across 544 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • AstraZeneca$878
  • Boehringer Ingelheim$781
  • GSK$462
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$9,552100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,552 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$18,087
Medicare patients
81
Services billed
210

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide87$104,930
JardianceEmpagliflozin87$94,227
EliquisApixaban85$90,475
CreonLipase/Protease/Amylase11$84,219
TrulicityDulaglutide40$58,230
MounjaroTirzepatide45$56,515
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$53,191
XareltoRivaroxaban37$44,888
FarxigaDapagliflozin Propanediol26$36,580
Soliqua 100-33Insulin Glargine/Lixisenatide20$20,296
Stiolto RespimatTiotropium Br/Olodaterol Hcl17$17,270
GemtesaVibegron18$17,092
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$16,805
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr31$16,150
Icosapent Ethyl28$11,711

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$1,081$114,74585 claims
Boehringer IngelheimJardiance, Stiolto Respimat$781$111,498104 claims
Novo NordiskOzempic$1,183$104,93087 claims
PfizerEliquis, Paxlovid$299$91,765100 claims
AbbVieCreon, Synthroid$1,229$89,70676 claims
GSKTrelegy Ellipta, Anoro Ellipta$462$69,34187 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$878$59,77667 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$136$20,29620 claims
Sumitomo Pharma America, Inc.Gemtesa$74$17,09218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Elma

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →